Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit model

June 4, 2018, The Company of Biologists

Scientists rely on the use of animal models to improve our understanding of lethal muscle-wasting disease Duchenne muscular dystrophy (DMD), and to develop safe new therapies. A newly developed rabbit model, created through the use of CRISPR/Cas-9 genome editing, exhibits greater clinical similarity to human patients than the mouse models currently in use, with huge potential to advance DMD research.

The muscle weakness that defines DMD first manifests in the hips and pelvis of affected boys at around four years old. This X-linked recessive disease affects around 1 in 3500 live male births and is caused by a defective gene disrupting production of a protein called dystrophin, which is essential for keeping muscle fibres intact. As the disease develops, muscle loss progresses from upper legs to upper arms and shoulders, leading to increased difficulty in standing up, climbing stairs and walking. By the time the boys reach their early teens, DMD also begins to affect the respiratory muscles and heart, which until recently meant that affected individuals did not survive much beyond their teen years. Improved medical care means that life expectancy has increased, with survival into the early 30s or even 40s becoming more common. However, there is still no cure and most current treatments focus on slowing and controlling onset of symptoms through drugs such as a steroids, physical therapy and orthopaedic appliances to improve mobility.

New gene therapy treatments that will target the affected gene to allow production of some level of functional dystrophin are under development, with a small number of drugs already commercially available. However, the available drugs target only a small percentage of the different dystrophin gene mutations that cause DMD. An important part of research into the physiological causes and testing of new therapies for any disease is the use of animal models. Previously, the vast majority of research into DMD has been conducted in mice, but despite a large number of potential treatments having been identified using mouse models, physiological differences between mice and humans means that relatively few have been translated to successful clinical trials. Dog models replicate human DMD better than mice as their physiology is more similar, and pig models for DMD are also under development. However, although large animal models have great potential for increasing our understanding of DMD and the development of new therapies, their use is expensive and limited to only a few facilities around the world. To fill the current gaps in animal models available for DMD research, new research published in open access journal Disease Models & Mechanisms reveals a novel rabbit model, created through CRISPR/Cas9 embryonic , by a team of scientists based at Jilin University, China and The Ohio State University Wexner Medical Center, USA. Crucially for successful DMD research and potential translation to preclinical studies and human clinical trials, the rabbits exhibit many of the same typical signs of muscular dystrophy as DMD patients, including severely impaired physical activity, elevated serum creatine kinase levels, progressive muscle loss and damage to heart muscle.

Accelerating developments with CRISPR/Cas9

Key to the development of this was the CRISPR/Cas9 genome editing technology that has revolutionised many aspects of modern biomedical research. Lead researcher Dr. Renzhi Han explains that "While it used to take two to three years to generate a knockout mouse model, now with CRISPR/Cas9, it takes only months to generate knockout models of various species such as mice, rats, rabbits, dogs, pigs and even monkeys." Prior to genome editing technology, approaches to creating animal models involved turning off the entire gene linked to disease in humans. However, in many cases the mutation causing the disease involves only subtle changes to the gene. This means that disease pathogenesis may be specific to these individual mutations, and may not be well modelled simply by turning off the whole gene. Precise nucleotide manipulation with CRISPR-derived approaches allows the development of animal models that more accurately reflect the disease-causing mutation, and allows them to be developed within a much shorter time frame. In the most commonly used mouse model of DMD, disruption of the dystrophin gene occurs at a specific site, exon 23, resulting in loss of the protein. Using CRISPR/Cas9, Dr. Han and colleagues were able to specifically target a different region, exon 51, that is a common mutation 'hotspot' in the human gene. Paired with a physiology that is more similar to that of humans, this means that the rabbit model more closely replicates the dystrophin deficiency of human DMD.

Advancing the search for a breakthrough

Looking to the future, Dr. Han reflects, "We believe a better model will facilitate studies to advance the understanding of DMD and aid the development of novel therapies." Currently, the scientists are focused on developing novel therapeutic strategies for muscular dystrophies. Their recent research has demonstrated that CRISPR/Cas9 genome editing therapy can restore dystrophin expression and cardiac function in dystrophic mice. With the availability of the DMD rabbit , the team plan to collaborate with other labs to further test the feasibility of this and other therapeutic strategies, pushing for a breakthrough in DMD research.

Explore further: Researchers devise improved gene-editing process for Duchenne muscular dystrophy

More information: Tingting Sui et al, A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9, Disease Models & Mechanisms (2018). DOI: 10.1242/dmm.032201

Related Stories

Researchers devise improved gene-editing process for Duchenne muscular dystrophy

November 30, 2017
Regenerative medicine researchers at UT Southwestern Medical Center developed an improved and simplified gene-editing technique using CRISPR/Cas9 tools to correct a common mutation that causes Duchenne muscular dystrophy.

CRISPR used to treat Duchenne muscular dystrophy cells in the lab

February 1, 2018
A team of researchers from the U.S. and Germany describes a novel CRISPR approach to produce healthy heart muscle using pluripotent stem cells from Duchenne muscular dystrophy (DMD) patients. In their paper published on the ...

Gene-editing alternative corrects Duchenne muscular dystrophy

April 12, 2017
Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

Gene transfer corrects severe muscle defects in mice with Duchenne muscular dystrophy

July 27, 2017
Duchenne muscular dystrophy is a rapidly progressive disease that causes whole-body muscle weakness and atrophy due to deficiency in a protein called dystrophin. Researchers at the University of Missouri, National Center ...

Research toward healing the hearts of children with Duchenne

April 6, 2018
After a progressive weakening of the muscles takes away their motor skills, and then their abilities to stand and walk, most males with Duchenne muscular dystrophy die of heart and respiratory failure in their 20s.

Recommended for you

Everything big data claims to know about you could be wrong

June 19, 2018
When it comes to understanding what makes people tick—and get sick—medical science has long assumed that the bigger the sample of human subjects, the better. But new research led by UC Berkeley suggests this big-data ...

Are you sticking to your diet? Scientists may be able to tell from a blood sample

June 19, 2018
An analysis of small molecules called "metabolites" in a blood sample may be used to determine whether a person is following a prescribed diet, scientists at Johns Hopkins Bloomberg School of Public Health have shown.

Diagnosing and treating disorders of early sex development

June 19, 2018
Diagnosing, advising on and treating disorders of early sex development represent a huge medical challenge, both for those affected and for treating physicians. In contrast to the earlier view, DSD (Difference of Sex Development) ...

BPA can induce multigenerational effects on ability to communicate

June 18, 2018
Past studies have shown that biparental care of offspring can be affected negatively when females and males are exposed to bisphenol A (BPA); however, previous studies have not characterized how long-term effects of BPA exposure ...

New compound shown to be as effective as FDA-approved drugs against life-threatening infections

June 15, 2018
Purdue University researchers have identified  a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections ...

Foods combining fats and carbohydrates more rewarding than foods with just fats or carbs

June 14, 2018
Researchers show that the reward center of the brain values foods high in both fat and carbohydrates—i.e., many processed foods—more than foods containing only fat or only carbs. A study of 206 adults, to appear June ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.